Since 2017, The Biocodex Microbiota Foundation rewards national research initiatives which aim to understand the interaction between microbiota and different pathologies. By promoting scientists from around the world at a key moment in their career, the grant seeks to motivate researchers to continue to explore the world of gut microbiota.
The annual call for proposals is carried out in countries where Biocodex has a subsidiary presence. An independent local scientific committee – made up of individuals recognized for their expertise in the microbiota field – gathers all proposals and selects the winning project to be granted.
Biocodex Microbiota Foundation in collaboration with Biocodex Microbiota Institute put national winners in the spotlight through testimonies and interviews!
Since 2017, The Biocodex Microbiota Foundation rewards national research initiatives which aim to understand the interaction between microbiota and different pathologies. By promoting scientists from around the world at a key moment in their career, the grant seeks to motivate researchers.
Granted projects
2020
Regulation of gene expression in gut bacteria host microRNAs
Effect of the Nordic diet on composition and functional profile of faecal microbiota and symptoms of fatigue in patients with mild and moderate ulcerative colitis
Precision health approaches through machine learning of faecal microbiome data
Alteration of gut microbiota by Helicobacter pylori leading to the progression of liver diseases
Rôle du microbiote intestinal dans la pathogénie des maladies auto-immunes systémiques
Determination of the estrobolomic brain axis and its importance in Alzheimer’s disease
Détermination de facteurs microbiologiques prédictifs de mauvaise réponse au traitement néoadjuvant dans les cancers du rectum : focus sur les Escherichia coli productrices de cyclomodulines
Influence of hyperglycemia on the host-microbiome interactions during subgingival microbiome dysbiosis
Study of the gut human microbiome and its relationship with immunosuppressive pharmacotherapy in stable renal transplant patients